A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy with LY4337713 in Adults with FAP-Positive Solid Tumors (FiREBOLT)
Clinical Trial Grant
Awarded By
Lilly USA, LLC
Start Date
October 10, 2025
End Date
October 12, 2030
Awarded By
Lilly USA, LLC
Start Date
October 10, 2025
End Date
October 12, 2030